WINDLAS Windlas Biotech Q3 FY26 results (Oct–Dec 2025) and concall
Windlas Biotech delivered a strong Q3 FY26, with revenue growing 20% YoY to INR233 crores, driven by robust performance in its CDMO and Exports segments. The 9-month FY26 revenue reached INR666 crores, up 19% YoY, and EPS increased 12% to INR24.02. While Trade Generics growth was slower in Q3, the company is progressing with Plant 6 nearing mechanical completion and remains focused on strategic expansion and operational efficiencies amidst a consolidating regulatory environment.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 19.5%, net profit down 6.3% against the same quarter last year.
| Line item | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 175 | 187 | 195 | 203 | 210 +20% | 222 +19% | 233 +19% |
| EBITDA | 21 | 23 | 25 | 26 | 27 +29% | 29 +26% | 24 −4% |
| Net profit | 13 | 16 | 16 | 16 | 18 +38% | 18 +13% | 15 −6% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
